
Lauren C Harshman MD
Assistant Professor of Medicine, Oncology, Harvard Medical School; Co-director of the Kidney Cancer Program at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MAAssistant Professor of Medicine, Oncology, Harvard Medical School; Co-director of the Kidney Cancer Program at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA. She is the study chair for the phase 3 PROSPER RCC Trial investigating perioperative nivolumab in non-metastatic RCC including those with sarcomatoid differentiation.
Disclosures
Dr. Harshman's disclosures for last 36 months:
Advisory: Bayer, Genentech, Dendreon, Pfizer, Medivation/Astellas, Kew Group, Theragene, Corvus, Merck; (Exelixis after next week)
Research to the institution: Bayer, Sotio, Bristol-Myers Squib, Merck, Takeda, Dendreon/Valient, Jannsen, Medivation/Astellas, Genentech, Pfizer;
CME: PER, Applied Clinical Education
Travel: Sanofi, Bayer